Meriva®, a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: a pilot, product evaluation registry study.

摘要: INTRODUCTION The aim of this registry evaluation study was to compare, in symptomatic BPH patients, two management plans based on a currently validated standard treatment [defined as the best (BSM)] including or not curcumin (administered Meriva®) further complementary adjuvant element. Signs and symptoms were evaluated using International Prostate Symptom Score (IPSS). SUBJECTS, METHODS: carried out total 61 subjects. 33 subjects (mean age 58.6;5.3) completed survey with at least 24 weeks Meriva® association BSM. BSM-alone control group consisted 28 volunteers similar (58.4 years;3.4) severity condition. range inclusion 55-65. No other clinical metabolic problems present. administered dosage 2 tablets/day (2 x 500 mg Meriva®/day, corresponding 100 curcumin/day) compliance values > 95% by number tablets used according medical recommendation. drugs food supplement during study. RESULTS All IPSS scores, exception stream weakness score BSM group, improved (p<0.05 vs. inclusion) both groups. overall results significantly better than BSM-only (p<0.05). side effects recorded. quality life groups, but (p<0.01). There also more important decrease subclinical episodes urinary infections block COMMENTS In patients BPH, addition contributed reduction signs disease without causing any significant additional effect. This pilot experience suggests potential novel application curcumin, studies aimed selecting most appropriate dosages length well possibility longer treatments will, undoubtedly, validate optimize role BPH.